Walker 256 tümörlü ratlarda Argininle takviye edilen diyetin hayatta kalmaya etkisi

Yıl 2012, Cilt: 69 Sayı: 4, 225 - 228, 01.12.2012

Maria Rita Carvalho Garbi Novaes Fabiani Lage Rodrigues Beal Roberto Cañete Villafranca

Öz

Amaç: Bu çalışma Walker 256 tümörlü ratların %8’lik arginin içeren diyetle sağ kalım sürelerinin arttırılmasını değerlendirmek amacıyla yapılmıştır.Yöntem: Bu çalışma deneysel, rastgele ve çift kör metodla yapılmıştır. Deneyde ratlar 3 gruba ayrılmıştır. Birinci gruba placebo walker 256 tümör aşılanmasından 7 gün önce sonda yardımı ile su verilmiştir. İkinci grup tümör aşılamasından 48 saat sonra %8’lik arginin solüsyonu almıştır. Üçüncü grup ise tümör aşılamasından 7 gün önce %8’lik arginin solüsyonu ile beslenmeye başlanmıştır.Bulgular: Tümoral aşılamadan 7 gün önce beslenmeye başlayan üçüncü grup diğer iki gruba nazaran daha fazla hayatta kalmıştır. 21 gün p=0.0001 Aşılamadan 48 saat sonra beslenen grupta hayatta kalma süresi 20 gün p=0.0001 placebo grubuna nazaran daha fazladır.Sonuç: Sonuçlar göstermektedir ki Arginin takviyesi alan iki grup placebo grubuna nazaran hayatta kalma süresi açısından bundan fayda görmüşlerdir. Ayrıca arginin takviyesine tümör aşılamasından önce başlayan grupta bu etki daha fazladır

Anahtar Kelimeler

Arginin, kanser, hayatta kalım, Walker 256 tümörü

Survival of rats with Walker 256 Tumor after oral suplementation of arginine in the diet

Öz

Objective: This study was undertaken to assess the effect of L-arginine at 8% on extended survival of rats with Walker 256 tumor. Method: The study is experimental, randomized, double blind. The animals for this experiment were divided in 3 groups. The first group placebo received gavage with water, seven days before the inoculation of Walker 256 tumor. The second group received 8% L-arginine solution of caloric ingestion 48 hours after the tumoral inoculation. The third group received 8% L-arginine solution of total caloric ingestion, initiated seven days before the tumoral inoculation. Results: The third group, supplemented seven days before the tumoral inoculation, presented greater extended survival 21 days, p=0.0001 when compared to animals from the other two. Animals supplemented 48 hours after the tumoral inoculation presented greater extended survival 20 days, p=0.0001 when compared to the placebo group 19 days, p=0.0001 .Conclusion: The results suggest that both groups supplemented with 8% L-arginine presented beneficial results in respect to extended survival when compared to the placebo group, and better yet if the amino acid was administered before the tumoral inoculation

Anahtar Kelimeler

Arginine, cancer, survival, Walker 256 tumor

Kaynakça

• 1. Novaes MRCG, Beal FLR. Pharmacology of L-arginine in cancer patients. Rev Bras Cancerol, 2004; 50 (4): 321-5.
• 2. Novaes MRCG, Pantaleão C. Pharmacological effects of nutritional supplementation of arginine in gastrointestinal cancer patients. Brazilian Journal of Clinical Nutrition, 2004; 19(1): 26-31.
• 3. Organización Panamericana De La Salud, Programa Especial De Análisis De Salud. Iniciativa Regional de Datos Básicos en Salud; Sistema de Información Técnica en Salud. Washington DC, 2001. Available in:<http://www.paho.org/Spanish/sha/coredata/ tabulator/ newTabulator.htm> Access in: Feb. 2004.
• 4. Novaes MRCG, Lima LAM. Effect of dietetic supplementation with L-arginine in cancer patients. A review of the literature. Arch Latinoamer Nutr, 1999; 49: 301-6.
• 5. Novaes MRCG, Lima LAM, Novaes LCG, Souza MV. Metabolic and hemathological effects of dietary supplementation with arginine on rats bearing ascitic Walker 256 tumor. Ann Nutr Metab, 2004; 48: 404-8.
• 6. Poulin, E. Prophylactic nutrition. Can J Surg, 1991; 34 (6): 555-9.
• 7. Braga M, Gianotti L, Vignali A, Cestari A, Bisagni P, Di Carlo V. Immunonutrition in gastric cancer surgical patients. Nutrition, 1998; 14: 831-5.
• 8. Atkinson F, Sieffert E, Bihari D. A prospective, randomised, double-blind, controlled clinical trial of enteral immunonutrition in the critically ill. Crit Care Medicine, 1998; 26(7): 1164-72.
• 9. Mainous MR, Deitch E. Nutrition and infection. Surg. Clin. North Am. 1994; 74(3):659-76.
• 10. Saunders C, Nishikama R, Wolfe B. Surgical nutrition: a review. J. R. Coll Surg Edin, 1993; 38(4): 195-204.
• 11. Brennan MF. Malnutrition in patients with gastrointestinal malignancy. Significance and management. Dig Dis Sci, 1986; 31: 77-99.
• 12. Novaes, MRCG, Lima LAM, Sousa MV. Maillard’s reaction in parenteral solutions supplemented with arginine. Arch Latinoamer Nutr, 2001; 51: 265-8.
• 13. Novaes, MRCG, Pantaleão CM. Arginine biochemistry, physiology, and therapeutic implications in gastrointestinal cancer patients. Rev Cienc Med, 2005; 14(1): 67-77.
• 14. Novaes MRCG, Lima LAM, Ribeiro JEG, Magalhães AV, Sousa MV, Morhy L. Pharmacological effects of arginine supplementation in rats with Walker 256 solid tumor. Arch Latinoamer Nutr, 2000; 50: 230-6.
• 15. De Luis DA, Arranz M, Aller R, Izaola O, Cuellar L, Terroba MC. Immunoenhanced enteral nutrition, effect on inflammatory markers in head and neck cancer patients. Eur J Clin Nutr, 2005; 59 (1): 145-7.
• 16. Barbul A. Arginine: Biochemistry, physiology and therapeutic implications. J Parenter Enteral Nutr, 1986; 10: 227-38.
• 17. Gianotti L, Braga M, Nespoli L, Radaelli G, Beneduce A, Di Carlo V. A randomized controlled trial of preoperative oral supplementation with a specialized diet in patients with gastrointestinal cancer. Gastroenterology, 2002; 122 (7): 1763-70.
• 18. Heslin MJ, Brennan MF. Advances in perioperative nutrition: cancer. World J Surg, 2000; 24 (12): 1477-85.
• 19. Heyland DK, Novak F, Drover JW, Jain M, Su X, Suchner U. Should immunonutrition became routine in critically ill patients? A systematic review of evidence. JAMA, 2001; 286 (8): 944-53.
• 20. Van Borkhorst-De Van Der Schueren MAE, Quak JJ, von Blomberg-van der Flier BME, Kuik DJ, Langendoen SI, Snow GB et al. Effect of perioperative nutrition, with and without arginine supplementation, on nutritional status, immune function, postoperative morbidity, and survival in severely malnourished head and neck cancer patients. Am J Clin Nutr, 2001; 73 (2): 323-32.
• 21. Tachibana L, Mukai K, Moriguchi S, Takama S, Kishino Y. Evaluation of the effect of arginineenriched amino acid solution on tumor growth. J Parenter Enteral Nutr, 1985; 9: 428-34.
• 22. Webster NR, Galley HF. Nutrition in the critically ill patient. J R Coll Surg Edimb, 2000; 45(6): 373-9.
• 23. Reynolds JV, Daly JM, Shou J, Sigal R, Ziegler MM, Naji A. Immunological effects of arginine supplementation in tumor bearing and non tumor bearing hosts. Ann Surg, 1990; 211: 202-10.
• 24. Nitenberg G, Raynard B. Nutritional support of the cancer patients: issues and dilemmas. Crit Rew Oncol Hematol, 2000; 34 (2): 137-68.